Eisai Co., Ltd.: Ovarian Neoplasms trials

The registry lists 12 Ovarian Neoplasms studies with Eisai Co., Ltd. as lead sponsor. 1 are open to participants now and 6 have results posted.

Phase 1 7Phase 2 7Phase 3 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor TypesRecruitingNCT04300556Phase 1/2
• A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian CancerCompletedNCT02289950Phase 2Results posted
• E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125TerminatedNCT01133756Phase 1/2Results posted
• An Open Label Extension Study of the Efficacy of MORAb-003TerminatedNCT01018563Phase 2Results posted
• Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First RelapseTerminatedNCT00849667Phase 3Results posted
• An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian CancerTerminatedNCT00738699Phase 2Results posted
• Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based ChemotherapyCompletedNCT00318370Phase 2Results posted
• An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid TumorsCompletedNCT01618136Phase 1/2
• Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian CancerCompletedNCT01004380Phase 1
• Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian CancerCompletedNCT00428766Phase 1
• A Study of ZYC300 Administered With Cyclophosphamide Pre-DosingCompletedNCT00381173Phase 1
• A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung CancerCompletedNCT00325494Phase 1